ArticleCurrent microbiology2026
Building a Global Innovation Pipeline for Organometallic Antifungals Against Nakaseomyces glabratus: Correspondence on Maqueda-Cabrera and Cuéllar-Cruz.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maqueda-Cabrera and Cuéllar-Cruz reported dose-dependent activity of the organometallic compound N-(2-hydroxyethyl)ferroceneselenoamide (FE1) against Nakaseomyces glabratus in a Galleria mellonella infection model. FE1 at 20 mg/kg produced complete larval protection and reduced fungal burden relative to fluconazole tested at the same dose. These findings are promising but remain preliminary because only the reference strain CBS138 was evaluated and the compound's mechanism of action is unknown. Further work should test geographically and genetically diverse clinical isolates, azole- and echinocandin-resistant phenotypes, and other clinically important opportunistic yeasts. Mechanistic studies should examine fungal stress-response pathways, resistance evolution, toxicity, pharmacokinetics/pharmacodynamics, and larval immune responses. G. mellonella is best positioned as a pre-screening or intermediate-screening experimental model rather than a direct predictor of clinical efficacy. A staged programme that links reproducible invertebrate endpoints to mammalian validation and WHO fungal-priority objectives could clarify whether FE1 merits further development as an antifungal candidate.
Indexed as
Identifiers
42809055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.